The Leona M. and Harry B. Helmsley Charitable Trust

The APhA Foundation launches patient enrollment for a program to expand access to pharmacist-provided continuous glucose monitoring (CGM) devices and services

Retrieved on: 
Thursday, July 20, 2023
Medical Devices, Diabetes, Health Insurance, Philanthropy, Managed Care, Health, Pharmaceutical, General Health, Foundation, CGM, Insulin, Partnership, Pharmacy, The Leona M. and Harry B. Helmsley Charitable Trust, Multimedia, American Pharmacists Association, Pharmacist, Patient, SVP, Helmsley, Pharmaceutical industry, Nursing, Health care

The project is a pilot credentialing program for community pharmacists that aims to increase access to CGM and improve diabetes care.

Key Points: 
  • The project is a pilot credentialing program for community pharmacists that aims to increase access to CGM and improve diabetes care.
  • It does so by integrating CGM devices and support services into the pharmacist workflow and ensuring pharmacists receive equitable payment for these services from insurers.
  • Roughly 90 percent of Americans live within five miles of a pharmacy, and increasingly pharmacists offer patient care services for people with diabetes, but this does not currently include CGM services.
  • “Our partnership with The APhA Foundation gives us confidence that Project IMPACT: CGM Access will take us one step closer to making CGM services more accessible.”

Minutia, Oregon Health & Sciences University and Go Pen Win First-Ever American Diabetes Association Innovation Challenge

Retrieved on: 
Sunday, June 25, 2023
CGM, Insulin, American Diabetes Association, Oregon Health & Science University, Diabetes, LAUNCH (Innovation Challenge), Gestational diabetes, Woman, Innovation, T2DM, School, Type 1, Work, SAN, Faculty of Allied Health Sciences, University of Peradeniya, ADA, The Leona M. and Harry B. Helmsley Charitable Trust, Disease, Pharmaceutical industry, Medical device, Chionanthus

SAN DIEGO, June 24, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the winner of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas. The winners, Minutia, Oregon Health & Sciences University and Go Pen presented three unique and impactful solutions to a variety of diabetes challenges.  

Key Points: 
  • SAN DIEGO, June 24, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the winner of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA.
  • The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas.
  • The winners, Minutia, Oregon Health & Sciences University and Go Pen presented three unique and impactful solutions to a variety of diabetes challenges.
  • Winner: Oregon Health & Sciences University – Distal and proximal interventions that occur across all systems including healthcare, social services, home/neighborhoods, schools, employers, and communities all to improve diabetes outcomes.

Butterfly Network Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Semiconductor, Medical Devices, Health, Radiology, Technology, ACC, Partnership, International, Network, Face, The Leona M. and Harry B. Helmsley Charitable Trust, Journal of Veterinary Medical Education, Atomic emission spectroscopy, Software, E-commerce, Cardiology, History, Vet, Physical examination, Lung, POCUS, Interest, EBITDA, Journal, Butterfly network, Patient, Access code, AI, FDA, S&M, Family, NYSE, Helmsley, Video game, Nursing, Medical imaging, Cryptocurrency, Butterfly

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with handheld, whole-body ultrasound, today announced financial results for the quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with handheld, whole-body ultrasound, today announced financial results for the quarter ended March 31, 2023, and provided a business update.
  • Reported total revenue of $15.5 million for the first quarter of 2023, flat to the first quarter ended March 31, 2022.
  • Total gross margin for the first quarter was 58.7%, compared to 53.6% in the first quarter of 2022.
  • An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
    A conference call to review the first quarter 2023 financial results and provide a business update is scheduled for May 11, 2023, at 8:30 am Eastern Time.

Tidepool Announces FDA Clearance of Tidepool Loop

Retrieved on: 
Tuesday, January 24, 2023
Technology, Mobile, Wireless, Medical Devices, FDA, Diabetes, Health Technology, Software, Health, Data Management, Physician, CGM, AID, DXCM, Insulin, DIY, T1D, The Leona M. and Harry B. Helmsley Charitable Trust, Patient, News, GlySens ICGM, Apple Watch, Person, Partnership, IPhone, Multimedia, Leona Helmsley, Helmsley, ACE, JDRF, Pharmaceutical industry, Dexcom

Tidepool, a 501(c)3 nonprofit committed to empowering the next generation of innovations in diabetes management, today announced the FDA clearance of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in persons six years of age and greater.

Key Points: 
  • Tidepool, a 501(c)3 nonprofit committed to empowering the next generation of innovations in diabetes management, today announced the FDA clearance of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in persons six years of age and greater.
  • View the full release here: https://www.businesswire.com/news/home/20230124006085/en/
    Image of Tidepool Loop interface on iPhone and Apple Watch (Graphic: Business Wire)
    Tidepool Loop, a patient-led project, is the first application of its kind to receive clearance from the FDA, and is also the first to enable insulin delivery from a compatible Apple Watch.
  • “We knew this day would come, but we couldn’t have achieved it without the support of the entire diabetes community, including the FDA,” said Howard Look, CEO and co-founder of Tidepool.
  • We look forward to continuing to work with Tidepool to make open protocol a reality, and we anxiously await news on future AID systems that will utilize this tremendous platform.”
    With the clearance of Tidepool Loop, the organization is now finalizing agreements with device partners to create a seamless experience for both physicians prescribing Tidepool Loop and the patients using it.

Alberto Pugliese, M.D., Joins City of Hope as Director of The Wanek Family Project for Type 1 Diabetes and Chair of the Department of Diabetes Immunology

Retrieved on: 
Tuesday, October 18, 2022
LinkedIn, John Atkinson, Medicine, Joslin Diabetes Center, Instagram, CAR, University, National, Drug discovery, City, Metabolism, Weldon Humble, Haematopoietic system, YouTube, University of Miami, The Leona M. and Harry B. Helmsley Charitable Trust, Twitter, Tissue, Department, Clinical trial, Immune tolerance, University of Palermo (Buenos Aires), Pathology, Microbiology, Organization, Research, NIH, Division, Multimedia, Pacific Northwest Diabetes Research Institute, Technology, Transplant, City of Hope National Medical Center, Translational Genomics Research Institute, Immunotherapy, Genetics, Ruth B., City of Hope, Type 1 diabetes, Disease, Leonard M. Miller School of Medicine, Patient, American Diabetes Association, Harvard Medical School, JDRF, Immune system, Helmsley, Pharmaceutical industry, Facebook, Diabetes, Hope

LOS ANGELES, Oct. 18, 2022 /PRNewswire/ -- Alberto Pugliese , M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute .

Key Points: 
  • LOS ANGELES, Oct. 18, 2022 /PRNewswire/ -- Alberto Pugliese , M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute .
  • His work has contributed to a greater understanding of genetic and cellular mechanisms that regulate immunological self-tolerance, specifically to molecules targeted in diabetes.
  • Pugliese has provided seminal contributions in the field of type 1 diabetes genetics, immunology, pathology and clinical trials, and his work has been published in major international journals.
  • Pugliese comes to City of Hope by way of the University of Miami, where he served as The J. Enloe and Eugenia J. Dodson Chair in Diabetes Research.

JDRF Announces Launch of global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Time, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, CDN, Insulin, Industry, Diabetes, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, The Lancet, International Society, Diagnosis, IDF, Heart, Research, GLOBE, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Management, Medical device, Child, Index, Facebook, Instagram, T1D, Lilly

TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).

Key Points: 
  • TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).
  • The T1D Index and accompanying research has been published in the world leading diabetes and endocrinology medical journal, The Lancet Diabetes & Endocrinology.
  • This is why I am so proud that significant progress has been made to understand T1Ds global impact through the T1D Index.
  • It is a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, Multimedia, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, View, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

National Park Foundation and Helmsley Charitable Trust Continue to Enhance the Visitor Experience at Parks, Focusing Now on Bering Land Bridge National Preserve in Alaska

Retrieved on: 
Thursday, August 11, 2022
Badlands National Park, National park, Leona, Bering Strait, National Park Foundation, National Park Service, Knowledge, Superintendent, History, Little Bighorn Battlefield National Monument, Bering Land Bridge National Preserve, Will Shafroth, Helmsley, Nature, Culture, The Leona M. and Harry B. Helmsley Charitable Trust, Seward Peninsula, Health, Pharmaceutical industry, Road, Iñupiat

"The National Park Foundation is grateful to the Helmsley Charitable Trust for its ongoing commitment to expanding the visitor experience," said National Park Foundation President and CEO Will Shafroth.

Key Points: 
  • "The National Park Foundation is grateful to the Helmsley Charitable Trust for its ongoing commitment to expanding the visitor experience," said National Park Foundation President and CEO Will Shafroth.
  • "Helmsley is proud to again support the National Park Foundation to help enhance the visitor experience at what is more than a national park, but a national treasure."
  • "Quyanaq, thank you, to the Helmsley Charitable Trust for the generous support for Bering Land Bridge National Preserve and Sitnasuak Native Corporation," said Jeanette Koelsch, Superintendent of Bering Land Bridge National Preserve.
  • Bering Land Bridge National Preserve protects a small remnant of the land bridge that connected Asia and North America more than 10,000 years ago during the last Ice Age.

Research team wins NIH prize for plan to accelerate advances in spinal stimulation through autonomic neuromodulation

Retrieved on: 
Monday, July 25, 2022
Common Fund for Commodities, Christopher and Dana Reeve Foundation, National, Brain, Spinal cord, NIH, Craig, University, Spine, New Jersey Commission on Higher Education, Center, Heart rate, Kessler Institute for Rehabilitation, Neurostimulation, Research, Helmsley, Doctor of Philosophy, Kessler Foundation, Foundation, National Institutes of Health Common Fund, Reynolds Center, Rehabilitation, Family, Multimedia, University of Louisville School of Medicine, Disability, Caregiver, MD, Autonomic nervous system, The Leona M. and Harry B. Helmsley Charitable Trust, Applied Physics Laboratory, Medtronic, Paralysis, Condition, Blood pressure, TIM, Cognition, Employment, SPARC, Mobility, Pharmaceutical industry, Medical device

EAST HANOVER, N.J., July 25, 2022 /PRNewswire/ -- The pioneering collaborative work being performed by Kessler Foundation scientists in the Tim and Caroline Reynolds Center for Spinal Stimulation team has been recognized with the Neuromod Prize, a new initiative from the National Institutes of Health (NIH) Common Fund's Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. The Neuromod Prize aims to accelerate the development of neuromodulation therapies — targeted treatments that have the potential to treat a multitude of conditions through regulation of nervous system activity. The competition capitalizes on the rapid momentum in the field as innovators apply decades of research to the development of novel neuromodulation solutions to clinical challenges.

Key Points: 
  • The Neuromod Prize aims to accelerate the development of neuromodulation therapies targeted treatments that have the potential to treat a multitude of conditions through regulation of nervous system activity.
  • Team wins NIH prize for plan to accelerate advances in spinal stimulation through autonomic neuromodulation.
  • The team's winning proposal, which outlines a pathway to greater independence for individuals paralyzed by spinal cord injury, is titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury."
  • "By broadening the scope of our research in spinal stimulation, the Neuromod Prize is supporting research that promises to revolutionize the outlook for people with spinal cord injury.